Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials

Marit de Jong, H Bart van der Worp, Yolanda van der Graaf, Frank L J Visseren, Jan Westerink, Marit de Jong, H Bart van der Worp, Yolanda van der Graaf, Frank L J Visseren, Jan Westerink

Abstract

Background and aims: Pioglitazone targets multiple pathogenic pathways involved in the development of cardiovascular diseases (CVD). The aim of this systematic review and meta-analysis is to assess the effects of pioglitazone treatment on the secondary prevention of CVD.

Methods: Randomized-controlled trials of pioglitazone in patients with CVD were identified through PubMed, Embase, Cochrane and CINAHL, in a search up to May 2016. Studies were included if pioglitazone was compared with any control (usual care, placebo or active comparator) and if patients were previously diagnosed with CVD. The outcomes of interest included major adverse cardiovascular events (MACE), myocardial infarction (MI), stroke, all-cause mortality and heart failure (HF). All outcomes were compared by pooled risk ratios (RR) with a 95% confidence interval (CI). Pooled estimates were calculated using a random-effects model.

Results: Ten studies reported the effects of pioglitazone on any of the outcomes of interest. Pioglitazone reduced recurrent MACE (RR 0.74, 95% 0.60-0.92; I2 = 35), MI (RR 0.77, 95% CI 0.64-0.93; I2 = 0%), or stroke (RR 0.81, 95% CI 0.68-0.96; I2 = 0%). Pioglitazone did not reduce all-cause mortality (RR 0.94, 95% CI 0.81-1.08; I2 = 0%), whereas pioglitazone treatment was associated with an increased risk of HF (RR 1.33, 95% CI 1.14-1.54).

Conclusions: Pioglitazone lowers the risk of recurrent MACE, stroke, or MI in patients with clinical manifest vascular disease. Pioglitazone does not lower the risk for all-cause mortality, and increases the risk for the development of HF.

Keywords: Cardiovascular disease; Pioglitazone; Secondary prevention.

Figures

Fig. 1
Fig. 1
Flowchart
Fig. 2
Fig. 2
Forrest plots. Forrest plot for the effects of pioglitazone on major adverse cardiac/cardiovascular events (a), a composite of nonfatal myocardial infarction, nonfatal stroke and cardiovascular mortality (b) and myocardial infarction (c)
Fig. 3
Fig. 3
Forrest plots. Forrest plot for the effects of pioglitazone on stroke (a), stroke recurrence (b), all-cause mortality (c) and heart failure (d)

References

    1. Dhamoon MS, Sciacca RR, Rundek T, Sacco RL, Elkind MS. Recurrent stroke and cardiac risks after first ischemic stroke: the Northern Manhattan Study. Neurology. 2006;66:641–646. doi: 10.1212/01.wnl.0000201253.93811.f6.
    1. Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med. 2016;374:1321–1331. doi: 10.1056/NEJMoa1506930.
    1. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation. 2016;133:e38–e60. doi: 10.1161/CIR.0000000000000350.
    1. WHO. The top 10 causes of death. 2016. . Accessed 4 May 2016.
    1. Kessler T, Vilne B, Schunkert H. The impact of genome-wide association studies on the pathophysiology and therapy of cardiovascular disease. EMBO Mol Med. 2016;8:688–701. doi: 10.15252/emmm.201506174.
    1. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome an american heart association/national heart, lung, and blood institute scientific statement. Circulation. 2005;112:2735–2752. doi: 10.1161/CIRCULATIONAHA.105.169404.
    1. Wassink AMJ, Van Der Graaf Y, Olijhoek JK, Visseren FL. Metabolic syndrome and the risk of new vascular events and all-cause mortality in patients with coronary artery disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm. Eur Heart J. 2008;29:213–223. doi: 10.1093/eurheartj/ehm582.
    1. Tanaka R, Yamashiro K, Okuma Y, Shimura H, Nakamura S, Ueno Y, et al. Effects of pioglitazone for secondary stroke prevention in patients with impaired glucose tolerance and newly diagnosed diabetes: the J-SPIRIT study. J Atheroscler Thromb. 2015;22:1305–1316. doi: 10.5551/jat.30007.
    1. Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA. 2008;299:1561–1573. doi: 10.1001/jama.299.13.1561.
    1. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279–1289. doi: 10.1016/S0140-6736(05)67528-9.
    1. Giannini S, Serio M, Galli A. Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity. J Endocrinol Invest. 2004;27:982–991. doi: 10.1007/BF03347546.
    1. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature. 1998;391:79–82. doi: 10.1038/34178.
    1. Corzo C, Griffin PR. Targeting the peroxisome proliferator-activated receptor-γ to counter the inflammatory milieu in obesity. Diabetes Metab J. 2013;37:395–403. doi: 10.4093/dmj.2013.37.6.395.
    1. Quinn CE, Hamilton PK, Lockhart CJ, McVeigh GE. Thiazolidinediones: effects on insulin resistance and the cardiovascular system. Br J Pharmacol. 2008;153:636–645. doi: 10.1038/sj.bjp.0707452.
    1. Rewers M, Zaccaro D, D’Agostino R, Haffner S, Saad MF, Selby JV, et al. Insulin sensitivity, insulinemia, and coronary artery disease: the insulin resistance atherosclerosis study. Diabetes care. 2004;27:781–7. . Accessed 9 Jul 2016.
    1. Motoki T, Kurobe H, Hirata Y, Nakayama T, Kinoshita H, Rocco KA, et al. PPAR-γ agonist attenuates inflammation in aortic aneurysm patients. Gen Thorac Cardiovasc Surg. 2015;63:565–571. doi: 10.1007/s11748-015-0576-1.
    1. Xu W, Bi Y, Sun Z, Li J, Guo L, Yang T, et al. Comparison of the effects on glycaemic control and β-cell function in newly diagnosed type 2 diabetes patients of treatment with exenatide, insulin or pioglitazone: a multicentre randomized parallel-group trial (the CONFIDENCE study) J Intern Med. 2015;277:137–150. doi: 10.1111/joim.12293.
    1. Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 2002;87:2784–2791. doi: 10.1210/jcem.87.6.8567.
    1. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes. 2001;50:2094–2099. doi: 10.2337/diabetes.50.9.2094.
    1. DeFronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011;364:1104–1115. doi: 10.1056/NEJMoa1010949.
    1. Saremi A, Schwenke DC, Buchanan TA, Hodis HN, Mack WJ, Banerji M, et al. Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 2013;33:393–399. doi: 10.1161/ATVBAHA.112.300346.
    1. Martens FM, Visseren FL, De Koning EJ, Rabelink TJ. Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes. J Cardiovasc Pharmacol. 2005;46:773–77821. doi: 10.1097/01.fjc.0000187176.13403.05.
    1. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457–2471. doi: 10.1056/NEJMoa072761.
    1. The Cochrane Public Health Group Guide for developing a Cochrane protocol. 2011. . Accessed 3 May 2016.
    1. Quality of reporting of meta-analyses (QUORUM) checklist. 1–2. . Accessed 3 May 2016.
    1. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. . Accessed 9 Jul 2016.
    1. J.P. Higgins, Green S. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. Tabel 8.5a: The Cochrane Collaboration’s tool for assessing risk of bias. . Accessed 4 May 2016.
    1. Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. 9.5.2 Identifying and measuring heterogeneity. . Accessed 3 May 2016.
    1. Hong SJ, Choi SC, Cho JY, Joo HJ, Park JH, Yu CW, et al. Pioglitazone increases circulating microRNA-24 with decrease in coronary neointimal hyperplasia in type 2 diabetic patients- optical coherence tomography analysis. Circ J. 2015;79:880–888. doi: 10.1253/circj.CJ-14-0964.
    1. Lee HW, Lee HC, Kim BW, Yang MJ, Park JS, Oh JH, et al. Effects of low dose pioglitazone on restenosis and coronary atherosclerosis in diabetic patients undergoing drug eluting stent implantation. Yonsei Med J. 2013;54:1313–1320. doi: 10.3349/ymj.2013.54.6.1313.
    1. Suryadevara S, Ueno M, Tello-Montoliu A, Ferreiro JL, Desai B, Rollini F, et al. Effects of pioglitazone on platelet P2Y12-mediated signalling in clopidogrel-treated patients with type 2 diabetes mellitus. Thromb Haemost. 2012;108:930–936. doi: 10.1160/TH12-06-0397.
    1. Takagi T, Okura H, Kobayashi Y, Kataoka T, Taguchi H, Toda I, et al. A prospective, multicenter, randomized trial to assess efficacy of pioglitazone on in-stent neointimal suppression in type 2 diabetes: POPPS (prevention of in-stent neointimal proliferation by pioglitazone study) JACC Cardiovasc Interv. 2009;2:524–531. doi: 10.1016/j.jcin.2009.04.007.
    1. Kaneda H, Shiono T, Miyashita Y, Takahashi S, Taketani Y, Domae H, et al. Efficacy and safety of pioglitazone in patients with ST elevation myocardial infarction treated with primary stent implantation. Heart. 2009;95:1079–1084. doi: 10.1136/hrt.2008.162842.
    1. Nishio K, Sakurai M, Kusuyama T, Shigemitsu M, Fukui T, Kawamura K, et al. A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes. Diabetes Care. 2006;29:101–106. doi: 10.2337/diacare.29.01.06.dc05-1170.
    1. Wilcox R, Bousser MG, Betteridge DJ, Schernthaner G, Pirags V, Kupfer S, et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04) Stroke. 2007;38:865–873. doi: 10.1161/01.STR.0000257974.06317.49.
    1. Wilcox R, Kupfer S, Erdmann E. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10) Am Heart J. 2008;155:712–717. doi: 10.1016/j.ahj.2007.11.029.
    1. Liu J, Wang LN. Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in patients with stroke or transient ischaemic attack. Cochrane Database Syst Rev. 2015
    1. Liao H, Saver JL, Wu Y, Chen T, Lee M, Ovbiagele B. Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis. BMJ. 2017;7:1–13.
    1. Lee M, Saver JL, Liao HW, Lin CH, Ovbiagele B. Pioglitazone for secondary stroke prevention. Stroke. 2017;48:388–393. doi: 10.1161/STROKEAHA.116.013977.
    1. Varas-Lorenzo C, Margulis AV, Pladevall M, Riera-Guardia N, Calingaert B, Hazell L, et al. The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies. BMC Cardiovasc Disord. 2014;14:129. doi: 10.1186/1471-2261-14-129.
    1. Hernandez AV, Usmani A, Rajamanickam A, Moheet A. Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus. Am J Cardiovasc Drugs. 2011;11:115–128. doi: 10.2165/11587580-000000000-00000.
    1. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus. JAMA. 2007;298:1180. doi: 10.1001/jama.298.10.1180.
    1. Nitta Y, Tahara N, Tahara A, Honda A, Kodama N, Mizoguchi M, et al. Pioglitazone decreases coronary artery inflammation in impaired glucose tolerance and diabetes mellitus: evaluation by FDG-PET/CT imaging. JACC Cardiovasc Imaging. 2013;6:1172–1182. doi: 10.1016/j.jcmg.2013.09.004.
    1. Ogasawara D, Shite J, Shinke T, Watanabe S, Otake H, Tanino Y, et al. Pioglitazone reduces the necrotic-core component in coronary plaque in association with enhanced plasma adiponectin in patients with type 2 diabetes mellitus. Circ J. 2009;73:343–51. .
    1. Christoph M, Herold J, Berg-Holldack A, Rauwolf T, Ziemssen T, Schmeisser A, et al. Effects of the PPARγ agonist pioglitazone on coronary atherosclerotic plaque composition and plaque progression in non-diabetic patients: a double-center, randomized controlled VH-IVUS pilot-trial. Heart Vessels. 2015;30:286–295. doi: 10.1007/s00380-014-0480-0.
    1. Marx N, Wöhrle J, Nusser T, Walcher D, Rinker A, Hombach V, et al. Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled. Double-Blind Trial in Nondiabetic Patients. Circulation. 2005;112:2792–2798.
    1. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care. 2004;27:256–263. doi: 10.2337/diacare.27.1.256.
    1. Hughes AD, Park C, March K, Coady E, Khir A, Chaturvedi N, et al. A randomized placebo controlled double blind crossover study of pioglitazone on left ventricular diastolic function in type 2 diabetes. Int J Cardiol. 2013;167:1329–1332. doi: 10.1016/j.ijcard.2012.03.179.
    1. Ordu S, Ozhan H, Alemdar R, Aydin M, Basar C, Caglar O, et al. Pioglitazone improves ventricular diastolic function in patients with diabetes mellitus: a tissue Doppler study. Acta Cardiol. 2010;65:401–406.
    1. Terui G, Goto T, Katsuta M, Aoki I, Ito H. Effect of pioglitazone on left ventricular diastolic function and fibrosis of type III collagen in type 2 diabetic patients. J Cardiol. 2009;54:52–58. doi: 10.1016/j.jjcc.2009.03.004.
    1. Oe H, Nakamura K, Kihara H, Shimada K, Fukuda S, Takagi T, et al. Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial. Cardiovasc Diabetol. 2015;14:83. doi: 10.1186/s12933-015-0242-z.
    1. Clarke GD, Solis-Herrera C, Molina-Wilkins M, Martinez S, Merovci A, Cersosimo E, et al. Pioglitazone improves left ventricular diastolic function in subjects with diabetes. Diabetes care. 2017:dc170078. doi:10.2337/dc17-0078.
    1. Berlie HD, Kalus JS, Jaber LA. Thiazolidinediones and the risk of edema: a meta-analysis. Diabetes Res Clin Pract. 2007;76:279–289. doi: 10.1016/j.diabres.2006.09.010.
    1. Lu CJ, Sun Y, Muo CH, Chen RC, Chen PC, Hsu CY, et al. Risk of stroke with thiazolidinediones: a 10-year nationwide population-based cohort study. Cerebrovasc Dis. 2013;36:145–151. doi: 10.1159/000353679.
    1. Lewis JD, Habel LA, Quesenberry CP, Strom BL, Peng T, Hedderson MM, et al. Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA. 2015;314:265–277. doi: 10.1001/jama.2015.7996.
    1. Erdmann E, Charbonnel B, Wilcox RG, Skene AM, Massi-Benedetti M, Yates J, et al. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08) Diabetes Care. 2007;30:2773–2778. doi: 10.2337/dc07-0717.
    1. Tuccori M, Filion KB, Yin H, Yu OH, Platt RW, Azoulay L. Pioglitazone use and risk of bladder cancer: population based cohort study. BMJ. 2016;352:i1541. doi: 10.1136/bmj.i1541.
    1. Zhu ZN, Jiang YF, Ding T. Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials. Bone. 2014;68:115–123. doi: 10.1016/j.bone.2014.08.010.
    1. Levin D, Bell S, Sund R, Hartikainen SA, Tuomilehto J, Pukkala E, et al. Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia. 2015;58:493–504. doi: 10.1007/s00125-014-3456-9.
    1. Erdmann E, Song E, Spanheimer R, van Troostenburg de Bruyn A-R, Perez A. Observational follow-up of the PROactive study: a 6-year update. Diabetes Obes Metab. 2014;16:63–74. doi: 10.1111/dom.12180.
    1. Highlights of prescribing information. 2011. . Accessed 15 Sep 2017.
    1. American Diabetes Association. Diabetes care. American Diabetes Association. 2017;40(1). . Accessed 29 Sep 2017.
    1. Ou HT, Chang KC, Li CY, Wu JS. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study. Cardiovasc Diabetol. 2016;15:41. doi: 10.1186/s12933-016-0350-4.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner